GlaxoSmithKline (GSK.L) stock price, revenue, and financials

GlaxoSmithKline market cap is £83.5 b, and annual revenue was £30.82 b in FY 2018

£83.5 B

GSK.L Mkt cap, 21-May-2020

£7.8 B

GlaxoSmithKline Revenue Q2, 2019
GlaxoSmithKline Gross profit (Q2, 2019)5.2 B
GlaxoSmithKline Gross profit margin (Q2, 2019), %66.2%
GlaxoSmithKline Net income (Q2, 2019)1.1 B
GlaxoSmithKline EBIT (Q2, 2019)1.5 B
GlaxoSmithKline Cash, 30-Jun-20194.1 B
GlaxoSmithKline EV112.8 B

GlaxoSmithKline Revenue

GlaxoSmithKline revenue was £30.82 b in FY, 2018 which is a 2.1% year over year increase from the previous period.

Embed Graph

GlaxoSmithKline Revenue Breakdown

Embed Graph

GlaxoSmithKline revenue breakdown by business segment: 24.8% from Consumer Healthcare, 19.1% from Vaccines and 56.0% from Global Pharmaceuticals

GlaxoSmithKline revenue breakdown by geographic segment: 25.9% from Europe, 35.3% from International and 38.9% from US

GlaxoSmithKline Income Statement

Annual

GBPFY, 2016FY, 2017FY, 2018

Revenue

27.9b30.2b30.8b

Revenue growth, %

17%8%2%

Cost of goods sold

9.3b10.3b10.2b

Gross profit

18.6b19.8b20.6b

Gross profit Margin, %

67%66%67%

R&D expense

3.6b4.5b3.9b

General and administrative expense

9.4b9.7b9.9b

Operating expense total

16.0b15.8b15.1b

EBIT

2.6b4.1b5.5b

EBIT margin, %

9%14%18%

Interest expense

736.0m734.0m798.0m

Interest income

72.0m65.0m81.0m

Pre tax profit

1.9b3.5b4.8b

Income tax expense

877.0m1.4b754.0m

Net Income

1.1b2.2b4.0b

EPS

0.20.30.7

GlaxoSmithKline Balance Sheet

Annual

GBPFY, 2016FY, 2017FY, 2018

Cash

4.9b3.8b3.9b

Accounts Receivable

6.0b6.0b6.4b

Inventories

5.1b5.6b5.5b

Current Assets

16.7b15.9b16.9b

PP&E

10.8b10.9b11.1b

Goodwill

6.0b5.7b5.8b

Total Assets

59.1b56.4b58.1b

Accounts Payable

12.0b21.0b14.0b

Short-term debt

4.1b2.8b5.8b

Current Liabilities

19.0b26.6b22.5b

Long-term debt

14.7b14.3b20.3b

Non-Current Liabilities

35.1b26.3b31.9b

Total Debt

18.8b17.1b26.1b

Total Liabilities

54.1b52.9b54.4b

Common Stock

1.3b1.3b1.3b

Additional Paid-in Capital

3.0b3.0b3.1b

Retained Earnings

(5.4b)(6.5b)(2.1b)

Total Equity

5.0b3.5b4.4b

Debt to Equity Ratio

3.8 x4.9 x6 x

Debt to Assets Ratio

0.3 x0.3 x0.4 x

Financial Leverage

11.9 x16.2 x13.3 x

GlaxoSmithKline Cash Flow

Annual

GBPFY, 2016FY, 2017FY, 2018

Net Income

1.1b2.2b4.0b

Depreciation and Amortization

1.9b3.0b1.8b

Cash From Operating Activities

6.5b6.9b8.4b

Purchases of PP&E

(1.5b)(1.5b)(1.3b)

Capital Expenditures

(809.0m)(657.0m)(452.0m)

Cash From Investing Activities

(1.3b)(1.4b)(1.6b)

Short-term Borrowings

(919.0m)(3.2b)(2.0b)

Long-term Borrowings

(18.0m)(23.0m)(28.0m)

Dividends Paid

(4.8b)(3.9b)(3.9b)

Cash From Financing Activities

(6.4b)(6.4b)(6.4b)

Net Change in Cash

(1.2b)(905.0m)479.0m

Interest Paid

732.0m781.0m766.0m

Income Taxes Paid

1.6b1.3b1.3b

Free Cash Flow

5.7b6.3b8.0b

GlaxoSmithKline Ratios

GBPY, 2019

EV/EBIT

76 x

EV/CFO

55 x

EV/FCF

69.9 x

Debt/Equity

11.3 x

Debt/Assets

0.5 x

Financial Leverage

21.4 x

GlaxoSmithKline Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Volume of Medicines Produced

2 b1.90 b2.30 b

Vaccines

833 m798 m770 m

Consumer Healthcare Products Produced

5 b6.20 b3.80 b

Vaccine Doses Delivered per Day

2 m2 m2 m

Countries

100 100 100 100 100

Manufacturing Facilities

57 54 87

Markets

150 150 150

New Product Launches

50 40 30

Partners

1.50 k1.50 k2 k

GlaxoSmithKline Sustainability Metrics

 FY, 2018

Water Used (Tankers)

190 k cubic meters

Water Used (Municipal)

9.23 m cubic meters

Water Used (Groundwater)

3.52 m cubic meters

Water Used

12.94 m cubic meters

Wastewater Discharged

10.20 m cubic meters

Waste Generated

126.30 k tonnes

Total Energy Used

15.20 m GJ

Number of Lost Time Accidents

303

Nonhazardous Waste (Landfilled)

3.70 k tonnes

Hazardous Waste (Landfilled)

200 tonnes

Greenhouse Gas Emissions (Scope 2)

606 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1)

823 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1 and Scope 2)

1.43 m metric tons of carbon dioxide equivalent

Energy Used from Renewable Energy Sources (Purchased)

200 k GJ

Energy Used from Renewable Energy Sources (On-Site Renewable Energy)

100 k GJ

Energy Used (Steam)

200 k GJ

Energy Used (Purchased Electricity)

5.80 m GJ

Energy Used (Natural Gas)

7.70 m GJ

Energy Used (Fuel and Other)

400 k GJ

Energy Used (Electricity)

5.90 m GJ

Energy Used (Coal)

200 k GJ

Energy Used (Biomass)

800 k GJ

Electricity Used from Renewable Energy Sources, percent

4.8%

Diversion Rate

77%

GlaxoSmithKline Human Capital

GlaxoSmithKline's employees are reported to be approximately 45% female and 55% male.

Gender

FY, 2018
Female44.9 %
Male55.1 %

GlaxoSmithKline Employee Rating

3.95685 votes
Culture & Values
3.9
Work/Life Balance
3.9
Senior Management
3.3
Salary & Benefits
3.9
Career Opportunities
3.5
Source